Telix Pharmaceuticals shares lift after US regulatory progress
Make us a preferred source
Make us a preferred source on Google
The news: Telix Pharmaceuticals shares have lifted after the radiopharmaceutical company announced that its Gozellix imaging agent for prostate cancer has reached a milestone in being added to a US patient reimbursement scheme.
The numbers: At 12:29pm AEST, Telix Pharmaceuticals shares had lifted 5.7% to $25.41. The stock had been trading flat until the announcement was made to the exchange just after 11:40am.
The context: Effective from 1 October 2025, US Centers for Medicare and Medicaid Services (CMS) will recognise the newly assigned permanent Healthcare Common Procedure Coding System (HCPCS) code for Gozillex.
The assignment of the code is a key step in “supporting provider billing and reimbursement for Gozellix, and a further step toward receiving Transitional Pass-Through payment status” – a reimbursement scheme for new devices and drugs while CMS gathers additional cost data on the products.
What they said: Telix Americas chief executive Kevin Richardson said the assignment of the HCPCS code is “an important enabler for commercial scale-up and reimbursement of Gozellix in the US as we bring our next-generation… imaging agent to market”.
The source: ASX
